Restenosis

Mitral restenosis.

Restenosis: delineating the numerous causes of drug-eluting stent restenosis.

In the past decade, tremendous progress has been made in reducing the incidence of restenosis with the advent of the drug-eluting stent (DES). With “plain old balloon angioplasty,” rates of acute and chronic vessel occlusion were unacceptably high at 30% to 60%, secondary to acute and chronic recoil and constrictive remodeling. The advent of bare-metal stents (BMS) appeared to eliminate the iss...

PTEN-uating restenosis.

Within the last few years, the lipid phosphatase PTEN has gained increasing attention.1 Initially described as a tumor suppressor gene, the function of PTEN meanwhile ranges from the regulation of the immune system to the recently established important function in neuronal growth.1,2 On a cellular level, PTEN interferes with cell proliferation, survival, and growth. These effects are not restri...

Ubiquitin, Proteasome, and Restenosis

In the present issue of Circulation, Meiners and his colleagues1 show that local application of a proteasome inhibitor resulted in significant inhibition of intimal hyperplasia in a balloon injury model in rat carotid artery. This report is of interest because it identifies a novel target for the treatment of restenosis and introduces a rapidly developing field in basic science to cardiovascula...

Reducing In-Stent Restenosis

All animal procedures were performed in accordance with UK Home Office Guidance on the operation of the Animals (Scientific Procedures) Act 1986 and institutional ethical approval (PPL60/4114 and PPL 60/4429). Male white Landrace pigs (SAC Commercial Ltd, Edinburgh, UK) and miR-21 knockout mice (1) were maintained on a 12 hour light/dark cycle with free access to food and water at a designated ...